All Stories

  1. Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases

    Article • Expert Review of Clinical Immunology, June 2019, Taylor & Francis

    Dr Adam S Cheifetz

  2. Systematic analysis of the quality of the scientific evidence and conflicts of interest in osteoarthritis of the hip and knee practice guidelines

    Article • Seminars in Arthritis and Rheumatism, February 2016, Elsevier

    Dr Adam S Cheifetz

  3. It Is Time to Treat to Trough: Staying Ahead of the Curve in Biologic Testing

    Article • Clinical Gastroenterology and Hepatology, December 2015, Elsevier

    Dr Adam S Cheifetz

  4. Adherence to Rectal Mesalamine in Patients with Ulcerative Colitis

    Article • Inflammatory Bowel Diseases, December 2015, Wolters Kluwer Health

    Dr Adam S Cheifetz

  5. Heightened Expression of CD39 by Regulatory T Lymphocytes Is Associated with Therapeutic Remission in Inflammatory Bowel Disease

    Article • Inflammatory Bowel Diseases, December 2015, Wolters Kluwer Health

    Dr Adam S Cheifetz

  6. Surgery for Ulcerative Colitis Is Associated with a High Rate of Readmissions at 30 Days

    Article • Inflammatory Bowel Diseases, September 2015, Wolters Kluwer Health

    Dr Adam S Cheifetz

  7. In Vitro Fertilization in Women With Inflammatory Bowel Disease Is as Successful as in Women From the General Infertility Population

    Article • Clinical Gastroenterology and Hepatology, September 2015, Elsevier

    Dr Adam S Cheifetz

  8. Reply to Use of CT Scan in Ulcerative Colitis Patients Presenting to the Emergency Department

    Article • Inflammatory Bowel Diseases, August 2015, Wolters Kluwer Health

    Dr Adam S Cheifetz

  9. Immune-mediated Reactions to Anti-tumor Necrosis Factors in Inflammatory Bowel Disease

    Article • Inflammatory Bowel Diseases, May 2015, Wolters Kluwer Health

    Dr Adam S Cheifetz

  10. Utility of CT in the Emergency Department in Patients with Ulcerative Colitis

    Article • Inflammatory Bowel Diseases, April 2015, Wolters Kluwer Health

    Dr Adam S Cheifetz

  11. Tu1838 Gene Expression in Luminal Extracellular Vesicles (EVS) in Patients With Inflammatory Bowel Disease (IBD)

    Article • Gastroenterology, April 2015, Elsevier

    Dr Adam S Cheifetz

  12. Su1202 Utility of Emergency Room Use of Abdominal Pelvic Computed Tomography in the Clinical Management of Crohn's Disease

    Article • Gastroenterology, April 2015, Elsevier

    Dr Adam S Cheifetz

  13. Sa1273 Efficacy and Safety of Retreatment With Vedolizumab in Patients With Crohn's Disease

    Article • Gastroenterology, April 2015, Elsevier

    Dr Adam S Cheifetz

  14. Sa1272 Efficacy and Safety of Retreatment With Vedolizumab in Patients With Ulcerative Colitis

    Article • Gastroenterology, April 2015, Elsevier

    Dr Adam S Cheifetz

  15. Sa1298 Perceived Wellbeing in Celiac Disease; Association With Patient Reported Outcomes, Clinical Indices and Biologic Parameters

    Article • Gastroenterology, April 2015, Elsevier

    Dr Adam S Cheifetz

  16. Sa1761 Anti-TNF Therapy Switches on CD39+ FoxP3 Tregs in Association With Symptomatic and Endoscopic Remission in IBD

    Article • Gastroenterology, April 2015, Elsevier

    Dr Adam S Cheifetz

  17. Biologic Concentration Testing in Inflammatory Bowel Disease

    Article • Inflammatory Bowel Diseases, January 2015, Wolters Kluwer Health

    Dr Adam S Cheifetz

  18. In Vitro Fertilization Is Successful in Women With Ulcerative Colitis and Ileal Pouch Anal Anastomosis

    Article • The American Journal of Gastroenterology, December 2014, Wolters Kluwer Health

    Dr Adam S Cheifetz

  19. Ulcerative Colitis

    Article • Mayo Clinic Proceedings, November 2014, Elsevier

    Dr Adam S Cheifetz

  20. Proactive Therapeutic Concentration Monitoring of Infliximab May Improve Outcomes for Patients with Inflammatory Bowel Disease

    Article • Inflammatory Bowel Diseases, November 2014, Wolters Kluwer Health

    Dr Adam S Cheifetz

  21. Crohn Disease

    Article • JAMA, October 2014, American Medical Association (AMA)

    Dr Adam S Cheifetz

  22. Documented Compliance with Inflammatory Bowel Disease Quality Measures Is Poor

    Article • Digestive Diseases and Sciences, October 2014, Springer Science + Business Media

    Dr Adam S Cheifetz

  23. Miscellaneous Adverse Events with Biologic Agents (Excludes Infection and Malignancy)

    Article • Gastroenterology Clinics of North America, September 2014, Elsevier

    Dr Adam S Cheifetz

  24. High Self-efficacy Predicts Adherence to Surveillance Colonoscopy in Inflammatory Bowel Disease

    Article • Inflammatory Bowel Diseases, September 2014, Wolters Kluwer Health

    Dr Adam S Cheifetz

  25. Colonoscopy Is Appropriately Utilized In Most Cases Following a Fair Bowel Prep

    Article • The American Journal of Gastroenterology, August 2014, Wolters Kluwer Health

    Dr Adam S Cheifetz

  26. Attitudes to Mesalamine Questionnaire: A Novel Tool to Predict Mesalamine Nonadherence in Patients with IBD

    Article • The American Journal of Gastroenterology, June 2014, Wolters Kluwer Health

    Dr Adam S Cheifetz

  27. In reply–Clinical Practice Guidelines: Still Miles to Go…

    Article • Mayo Clinic Proceedings, June 2014, Elsevier

    Dr Adam S Cheifetz

  28. The Holistic Effects of Cannabis in Crohn's Disease

    Article • Clinical Gastroenterology and Hepatology, May 2014, Elsevier

    Dr Adam S Cheifetz

  29. Vitamin D Levels in Adults with Crohnʼs Disease Are Responsive to Disease Activity and Treatment

    Article • Inflammatory Bowel Diseases, May 2014, Wolters Kluwer Health

    Dr Adam S Cheifetz

  30. 211 A Pilot Study of Optimized Monotherapy With Infliximab for Patients With Inflammatory Bowel Disease

    Article • Gastroenterology, May 2014, Elsevier

    Dr Adam S Cheifetz

  31. Su1103 30 Day Readmissions Rate and Predictors of Readmission in Hospitalized Patients With Ulcerative Colitis

    Article • Gastroenterology, May 2014, Elsevier

    Dr Adam S Cheifetz

  32. Su1102 Compliance With American Gastroenterological Association Inflammatory Bowel Disease Quality Measures

    Article • Gastroenterology, May 2014, Elsevier

    Dr Adam S Cheifetz

  33. Tu1183 Impact of Inflammatory Bowel Disease on Mode of Child Delivery

    Article • Gastroenterology, May 2014, Elsevier

    Dr Adam S Cheifetz

  34. Mo1741 Crohn's Disease Is Associated With Altered Expression and Function of Plasma Membrane Ectonucleotidases

    Article • Gastroenterology, May 2014, Elsevier

    Dr Adam S Cheifetz

  35. 209 Prospective Therapeutic Drug Monitoring to Optimizing Infliximab (IFX) Maintenance Therapy in Patients With Inflammatory Bowel Disease (IBD)

    Article • Gastroenterology, May 2014, Elsevier

    Dr Adam S Cheifetz

  36. Sa1231 Elevated Serum IL-17 Levels in Crohn's Disease Correlate With Disease Activity but Do Not Predict Response to Infliximab

    Article • Gastroenterology, May 2014, Elsevier

    Dr Adam S Cheifetz

  37. 1055 Recommendations for Creating a High Quality Endoscopy Report for Inflammatory Bowel Disease Patients: Results From a RAND-Appropriateness Panel

    Article • Gastroenterology, May 2014, Elsevier

    Dr Adam S Cheifetz

  38. Characteristics of Inflammatory Bowel Disease Serology in Patients With Indeterminate Colitis

    Article • Journal of Clinical Gastroenterology, April 2014, Wolters Kluwer Health

    Dr Adam S Cheifetz

  39. The Burden of Inflammatory Bowel Disease

    Article • Inflammatory Bowel Diseases, March 2014, Wolters Kluwer Health

    Dr Adam S Cheifetz

  40. Characterization of Human CD39+ Th17 Cells with Suppressor Activity and Modulation in Inflammatory Bowel Disease

    Article • PLoS ONE, February 2014, PLOS

    Dr Adam S Cheifetz

  41. The Role of Mucosal Healing in the Treatment of Patients With Inflammatory Bowel Disease

    Article • Current Treatment Options in Gastroenterology, January 2014, Springer Science + Business Media

    Dr Adam S Cheifetz

  42. The Role of the Food and Drug Administration in Medical Therapy for Ulcerative Colitis

    Article • January 2014, Springer Science + Business Media

    Dr Adam S Cheifetz

  43. Systematic Analysis Underlying the Quality of the Scientific Evidence and Conflicts of Interest in Interventional Medicine Subspecialty Guidelines

    Article • Mayo Clinic Proceedings, January 2014, Elsevier

    Dr Adam S Cheifetz

  44. P-085 YI Infliximab Dosing Changes Based on Trough Levels in a Cohort of IBD Patients in Clinical Remission

    Article • Inflammatory Bowel Diseases, December 2013, Wolters Kluwer Health

    Dr Adam S Cheifetz

  45. P-084 Self-Reported Health Maintenance Behaviors in a Population of Patients with Ulcerative Colitis

    Article • Inflammatory Bowel Diseases, December 2013, Wolters Kluwer Health

    Dr Adam S Cheifetz

  46. An Appraisal of the Current State of Gastroenterology Practice Guidelines

    Article • Gastroenterology, December 2013, Elsevier

    Dr Adam S Cheifetz

  47. Lectin-reactive Anti-α-Gal in Patients with Crohnʼs Disease

    Article • Inflammatory Bowel Diseases, December 2013, Wolters Kluwer Health

    Dr Adam S Cheifetz

  48. Hickam's Dictum in a Patient With Diarrhea

    Article • Gastroenterology, November 2013, Elsevier

    Dr Adam S Cheifetz

  49. Systematic Analysis Underlying the Quality of the Scientific Evidence and Conflicts of Interest in Gastroenterology Practice Guidelines

    Article • The American Journal of Gastroenterology, November 2013, Wolters Kluwer Health

    Dr Adam S Cheifetz

  50. Prevalence and Lifetime Risk of Endoscopy-related Complications Among Patients With Inflammatory Bowel Disease

    Article • Clinical Gastroenterology and Hepatology, October 2013, Elsevier

    Dr Adam S Cheifetz

  51. Efficacy and Safety of Natalizumab in Crohn’s Disease Patients Treated at 6 Boston Academic Hospitals

    Article • Inflammatory Bowel Diseases, October 2013, Wolters Kluwer Health

    Dr Adam S Cheifetz, Privat Docent, Master of Science in Epidemiology Pascal Juillerat

  52. Histologic Markers of Inflammation in Patients With Ulcerative Colitis in Clinical Remission

    Article • Clinical Gastroenterology and Hepatology, August 2013, Elsevier

    Dr Adam S Cheifetz

  53. Management of Active Crohn Disease

    Article • JAMA, May 2013, American Medical Association (AMA)

    Dr Adam S Cheifetz

  54. Su1229 Predictors of Response to Infliximab As Salvage Therapy for Severe Steroid Refractory Ulcerative Colitis

    Article • Gastroenterology, May 2013, Elsevier

    Dr Adam S Cheifetz

  55. Su1230 Venous Thromboembolism Prophylaxis Use in Patients Admitted With Severe Ulcerative Colitis

    Article • Gastroenterology, May 2013, Elsevier

    Dr Adam S Cheifetz

  56. 975 Novel Associations of Uncommon Crohn's Disease Risk Alleles With Higher Frequencies in the Ashkenazi Jewish Population

    Article • Gastroenterology, May 2013, Elsevier

    Dr Adam S Cheifetz

  57. Mo1101 Systematic Analysis of the Quality Underlying the Scientific Evidence and Conflicts of Interest in Interventional Subspecialty Practice Guidelines

    Article • Gastroenterology, May 2013, Elsevier

    Dr Adam S Cheifetz

  58. 979 Impact of Concomitant Immunomodulator Treatment on Efficacy and Safety of Anti-TNF Therapy in Crohn's Disease: A Meta-Analysis of Placebo Controlled Trials With Individual Patient-Level Data

    Article • Gastroenterology, May 2013, Elsevier

    Dr Adam S Cheifetz

  59. Evaluation of the small bowel in inflammatory bowel disease

    Article • Expert Review of Gastroenterology & Hepatology, March 2013, Taylor & Francis

    Dr Adam S Cheifetz

  60. Factors that Affect Adherence to Surveillance Colonoscopy in Patients with Inflammatory Bowel Disease

    Article • Inflammatory Bowel Diseases, March 2013, Wolters Kluwer Health

    Dr Adam S Cheifetz

  61. Predictors of Endoscopic Inflammation in Patients With Ulcerative Colitis in Clinical Remission

    Article • Inflammatory Bowel Diseases, March 2013, Wolters Kluwer Health

    Dr Adam S Cheifetz

  62. The Crohn's disease activity index (CDAI) is similarly elevated in patients with Crohn's disease and in patients with irritable bowel syndrome

    Article • Alimentary Pharmacology & Therapeutics, February 2013, Wiley

    Dr Adam S Cheifetz

  63. A Random Urine Test Can Identify Patients at Risk of Mesalamine Non-Adherence: A Prospective Study

    Article • The American Journal of Gastroenterology, January 2013, Wolters Kluwer Health

    Dr Adam S Cheifetz

  64. Systematic Review and Meta-analysis on the Effects of Thiopurines on Birth Outcomes from Female and Male Patients with Inflammatory Bowel Disease

    Article • Inflammatory Bowel Diseases, January 2013, Wolters Kluwer Health

    Dr Adam S Cheifetz

  65. Varicella zoster virus infection in inflammatory bowel disease

    Article • Inflammatory Bowel Diseases, December 2012, Wolters Kluwer Health

    Dr Adam S Cheifetz

  66. Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis

    Article • The American Journal of Gastroenterology, November 2012, Wolters Kluwer Health

    Dr Adam S Cheifetz

  67. CD73 is a phenotypic marker of effector memory Th17 cells in inflammatory bowel disease

    Article • European Journal of Immunology, October 2012, Wiley

    Dr Adam S Cheifetz

  68. Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohnʼs disease

    Article • Inflammatory Bowel Diseases, September 2012, Wolters Kluwer Health

    Dr Adam S Cheifetz

  69. Comparative effectiveness research in inflammatory bowel disease: prospects and challenges

    Article • Expert Review of Gastroenterology & Hepatology, August 2012, Taylor & Francis

    Dr Adam S Cheifetz

  70. Mycobacterium marinum: An Increasingly Common Opportunistic Infection in Patients on Infliximab

    Article • The American Journal of Gastroenterology, August 2012, Wolters Kluwer Health

    Dr Adam S Cheifetz

  71. Doctor Message Can Alter Patientsʼ Behavior and Attitudes Regarding Inflammatory Bowel Disease and Colon Cancer

    Article • Inflammatory Bowel Diseases, August 2012, Wolters Kluwer Health

    Dr Adam S Cheifetz

  72. Screening for tuberculosis and hepatitis B prior to the initiation of anti-tumor necrosis therapy

    Article • Inflammatory Bowel Diseases, June 2012, Wolters Kluwer Health

    Dr Adam S Cheifetz

  73. Patient-Specific Approach to Combination Versus Monotherapy with the Use of Antitumor Necrosis Factor α Agents for Inflammatory Bowel Disease

    Article • Gastroenterology Clinics of North America, June 2012, Elsevier

    Dr Adam S Cheifetz

  74. 304 In Vitro Fertilization in Patients With Ulcerative Colitis and Ileal Pouch Anal Anastomosis

    Article • Gastroenterology, May 2012, Elsevier

    Dr Adam S Cheifetz

  75. Mo1691 Predictors of Deep Remission in Patients With Inactive Ulcerative Colitis

    Article • Gastroenterology, May 2012, Elsevier

    Dr Adam S Cheifetz

  76. Abdominal phlegmons in Crohnʼs disease: Outcomes following antitumor necrosis factor therapy

    Article • Inflammatory Bowel Diseases, April 2012, Wolters Kluwer Health

    Dr Adam S Cheifetz

  77. One Drug or Two: Do Patients on Biologics Need Concurrent Immunomodulation?

    Article • January 2012, Wiley

    Dr Adam S Cheifetz

  78. Treg CD39 expression as a modulator of intestinal inflammation in Crohnʼs Disease

    Article • Inflammatory Bowel Diseases, December 2011, Wolters Kluwer Health

    Dr Adam S Cheifetz

  79. Cryptosporidiosis masquerading as a Crohnʼs flare

    Article • Inflammatory Bowel Diseases, October 2011, Wolters Kluwer Health

    Dr Adam S Cheifetz

  80. Varicella zoster meningoradiculitis in Crohnʼs disease treated with 6-mercaptopurine

    Article • Inflammatory Bowel Diseases, August 2011, Wolters Kluwer Health

    Dr Adam S Cheifetz

  81. Capsule endoscopy for small-bowel evaluation in Crohn's disease

    Article • Gastrointestinal Endoscopy, July 2011, Elsevier

    Dr Adam S Cheifetz

  82. Infliximab decreases colectomy rates in moderate to severe ulcerative colitis

    Article • Inflammatory Bowel Diseases, July 2011, Wolters Kluwer Health

    Dr Adam S Cheifetz

  83. Cyclosporine is Safe and Effective in Patients With Severe Ulcerative Colitis

    Article • Journal of Clinical Gastroenterology, February 2011, Wolters Kluwer Health

    Dr Adam S Cheifetz

  84. Vaccination in Inflammatory Bowel Disease

    Article • The American Journal of Gastroenterology, January 2011, Wolters Kluwer Health

    Dr Adam S Cheifetz

  85. Capsule Endoscopy in Suspected Crohn's Disease: “Yield” Does Not Equal “Diagnosis”

    Article • The American Journal of Gastroenterology, September 2010, Wolters Kluwer Health

    Dr Adam S Cheifetz

  86. The Appropriateness of Concomitant Immunomodulators With Anti–Tumor Necrosis Factor Agents for Crohn's Disease: One Size Does Not Fit All

    Article • Clinical Gastroenterology and Hepatology, August 2010, Elsevier

    Dr Adam S Cheifetz

  87. Impact of a patient-support program on mesalamine adherence in patients with ulcerative colitis — A prospective study

    Article • Journal of Crohn s and Colitis, June 2010, Oxford University Press (OUP)

    Dr Adam S Cheifetz

  88. Targeting TNF in postoperative recurrence of Crohnʼs disease

    Article • Inflammatory Bowel Diseases, December 2009, Wolters Kluwer Health

    Dr Adam S Cheifetz

  89. Interventions for prevention of post-operative recurrence of Crohn's disease

    Article • Cochrane Database of Systematic Reviews, October 2009, Wiley

    Dr Adam S Cheifetz

  90. Management of acute severe ulcerative colitis

    Article • Expert Review of Gastroenterology & Hepatology, August 2009, Taylor & Francis

    Dr Adam S Cheifetz

  91. The Utility of Capsule Endoscopy in Patients With Suspected Crohn's Disease

    Article • The American Journal of Gastroenterology, July 2009, Wolters Kluwer Health

    Dr Adam S Cheifetz

  92. Impact of Concomitant Immunomodulator Use on Long-Term Outcomes in Patients Receiving Scheduled Maintenance Infliximab

    Article • Digestive Diseases and Sciences, June 2009, Springer Science + Business Media

    Dr Adam S Cheifetz

  93. S1029 Clinical Use and Outcomes from IBD Serology Testing in a Tertiary Referral Center

    Article • Gastroenterology, May 2009, Elsevier

    Dr Adam S Cheifetz

  94. S1053 Impact of a Patient Support Program On Mesalamine Adherence in Patients with Ulcerative Colitis

    Article • Gastroenterology, May 2009, Elsevier

    Dr Adam S Cheifetz

  95. T1210 Meta-Analysis of Mesalamine in the Prevention of Post-Operative Recurrence of Crohn's Disease

    Article • Gastroenterology, May 2009, Elsevier

    Dr Adam S Cheifetz

  96. W2011 Meta-Analysis of Probiotics in the Prevention of Post-Operative Recurrence of Crohn's Disease

    Article • Gastroenterology, May 2009, Elsevier

    Dr Adam S Cheifetz

  97. How often is a diagnosis of ulcerative colitis changed to Crohnʼs disease and vice versa?

    Article • Inflammatory Bowel Diseases, October 2008, Wolters Kluwer Health

    Dr Adam S Cheifetz

  98. How often is a diagnosis of ulcerative colitis changed to Crohnʼs disease and vice versa?

    Article • Inflammatory Bowel Diseases, October 2008, Wolters Kluwer Health

    Dr Adam S Cheifetz

  99. M1137 The Natural History of Infusion Reactions in Infliximab Recipients

    Article • Gastroenterology, April 2008, Elsevier

    Dr Adam S Cheifetz

  100. M1136 The Natural History of Dysplasia in Inflammatory Bowel Disease: Influence of Disease Type and Dysplasia Morphology and Grade On Cancer Risk

    Article • Gastroenterology, April 2008, Elsevier

    Dr Adam S Cheifetz

  101. M1152 Long-Term Outcomes in Infliximab Recipients Are Independent of Concomitant Immunomodulator Use in Patients with Crohn's Disease

    Article • Gastroenterology, April 2008, Elsevier

    Dr Adam S Cheifetz

  102. S1214 How Do IBD Patients Get Their Information? a Look At IBD Information Resources and Perception of Doctor Message in Patients with Extensive Crohn's or Ulcerative Colitis

    Article • Gastroenterology, April 2008, Elsevier

    Dr Adam S Cheifetz

  103. W1232 Bridging Therapy with Cyclosporine and 6mp Significantly Reduces Long-Term Colectomy Rates in Patients with Severe Ulcerative Colitis

    Article • Gastroenterology, April 2008, Elsevier

    Dr Adam S Cheifetz

  104. Interventions for prevention of post-operative recurrence of Crohn's disease

    Article • January 2008, Wiley

    Dr Adam S Cheifetz

  105. Meta-Analysis of the Placebo Response in Ulcerative Colitis

    Article • Digestive Diseases and Sciences, October 2007, Springer Science + Business Media

    Dr Adam S Cheifetz

  106. Reducing the Torment of Diarrhea

    Article • Journal of Clinical Gastroenterology, October 2007, Wolters Kluwer Health

    Dr Adam S Cheifetz

  107. Response to Dr. Spada and Colleagues

    Article • The American Journal of Gastroenterology, July 2007, Wolters Kluwer Health

    Dr Adam S Cheifetz

  108. The Risk of Retention of the Capsule Endoscope in Patients with Known or Suspected Crohn's Disease

    Article • The American Journal of Gastroenterology, October 2006, Wolters Kluwer Health

    Dr Adam S Cheifetz

  109. Capsule Endoscopy Retention: Is it a Complication?

    Article • Journal of Clinical Gastroenterology, September 2006, Wolters Kluwer Health

    Dr Adam S Cheifetz

  110. Combined oral and topical mesalazine treatment for extensive ulcerative colitis

    Article • Nature Clinical Practice Gastroenterology &#38 Hepatology, May 2006, Springer Science + Business Media

    Dr Adam S Cheifetz

  111. Evidence for a genetic defect in oral tolerance induction in inflammatory bowel disease

    Article • Inflammatory Bowel Diseases, February 2006, Wolters Kluwer Health

    Dr Adam S Cheifetz

  112. Anti-Tumour Necrosis Factor Therapy for Ulcerative Colitis

    Article • Drugs, January 2006, Springer Science + Business Media

    Dr Adam S Cheifetz

  113. Thyroid cancer and Crohnʼs disease: Association or coincidence?

    Article • Inflammatory Bowel Diseases, January 2006, Wolters Kluwer Health

    Dr Adam S Cheifetz

  114. Infliximab: Use in inflammatory bowel disease

    Article • Current Treatment Options in Gastroenterology, June 2005, Springer Science + Business Media

    Dr Adam S Cheifetz

  115. Failure to Induce Oral Tolerance in Crohn's and Ulcerative Colitis Patients: Possible Genetic Risk

    Article • Annals of the New York Academy of Sciences, December 2004, Wiley

    Dr Adam S Cheifetz

  116. You Say Goodbye and I Say Aloe

    Article • Inflammatory Bowel Diseases, September 2004, Wolters Kluwer Health

    Dr Adam S Cheifetz

  117. The Diagnosis and Treatment of Pouchitis in Inflammatory Bowel Disease

    Article • Journal of Clinical Gastroenterology, May 2004, Wolters Kluwer Health

    Dr Adam S Cheifetz

  118. Small Bowel Obstruction — Indication or Contraindication for Capsule Endoscopy

    Article • Gastrointestinal Endoscopy, April 2004, Elsevier

    Dr Adam S Cheifetz

  119. The incidence and management of infusion reactions to infliximab: a large center experience

    Article • The American Journal of Gastroenterology, June 2003, Wolters Kluwer Health

    Dr Adam S Cheifetz